Frazier Life Sciences Management, L.P. Mereo Biopharma Group PLC Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q2 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 9,440,112 shares of MREO stock, worth $15.7 Million. This represents 1.35% of its overall portfolio holdings.
Number of Shares
9,440,112
Previous 7,819,863
20.72%
Holding current value
$15.7 Million
Previous $17.6 Million
45.4%
% of portfolio
1.35%
Previous 1.11%
Shares
4 transactions
Others Institutions Holding MREO
# of Institutions
97Shares Held
98.2MCall Options Held
2.28MPut Options Held
761K-
Janus Henderson Group PLC London, X017.7MShares$29.4 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$25.4 Million0.96% of portfolio
-
Mangrove Partners New York, NY8.64MShares$14.3 Million3.39% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$11.1 Million0.42% of portfolio
-
Alkeon Capital Management LLC New York, NY4.7MShares$7.8 Million0.02% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $207M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...